drugset
drugset / Trial / NCT01872832

Single and Multiple Dose Study in Japanese Subjects

NCT01872832 ↗

Phase 1 Completed 46 enrolled Ardea Biosciences, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will explore the safety, tolerability, and serum uric acid lowering effect of RDEA3170 in healthy Japanese males to allow comparison with the Western population.

Timeline

Start
2013-06
Primary completion
2013-09
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Verinurad Small molecule 2.5 mg —
Subject Verinurad Small molecule 5 mg —
Subject Verinurad Small molecule 10 mg —
Subject Verinurad Small molecule 15 mg —

Indications

gout